Competition law and commercial agreements

This subtopic contains guidance on EU level rules relating to competition law and commercial agreements.

The European Commission is wary of any arrangements which might restrict competition. Several types of commercial agreements may raise competition law concerns, such as:

  1. horizontal agreements

  2. vertical agreements

Analysing horizontal agreements under Article 101 TFEU

Horizontal agreements may involve arrangements between competitors. A key proposition underpinning EU competition law is that competing companies should act independently on markets. Horizontal cooperation can be beneficial for consumers and markets but involving competitors will be of particular concern from an EU competition law perspective where there is coordination on certain sensitive parameters (eg price and/or output) or where the cooperation enables collaborating parties with already strong market positions to gain, maintain or increase market power.

Practice Note: Analysing horizontal cooperation agreements under EU competition law considers the key EU competition rules to be borne in mind when drafting or reviewing a horizontal agreement between actual or potential competitors. The Practice Note sets out a process for assessing whether a horizontal agreement might be anti-competitive and the possibilities for exemption

To view the latest version of this document and thousands of others like it, sign-in with LexisNexis or register for a free trial.

Powered by Lexis+®
Latest EU Law News

Commission publishes updated clinical trials guidance package

The European Commission's Directorate-General for Health and Food Safety has published a comprehensive package of updated clinical trials guidance documents, all endorsed by the Clinical Trials Coordination and Advisory Group (CTAG) on 15 October 2025. The package includes new recommendations on criteria for selecting a reporting Member State under Article 85(2)(c) of the Clinical Trials Regulation, establishing a workshare criterion when proposed reporting Member States decline the role, which occurs in approximately 30% of applications. The Commission has updated its recommendation paper on decentralised elements in clinical trials (Version 02), superseding the December 2022 version, with revised national provision overviews and guidance on informed consent, investigational medicinal product delivery, and remote monitoring. A new recommendation paper addresses frequent issues identified during Part I and Part II assessments, based on feedback from national competent authorities and ethics committees, covering investigational medicinal product dossiers, protocols, and safety reporting. The package also includes revised guidance on auxiliary medicinal products, effective 1 December 2025 for new applications, featuring an updated classification system distinguishing between authorised, modified authorised, and unauthorised auxiliary medicinal products with corresponding application and safety reporting requirements.

View EU Law by content type :

Popular documents